NOVINKY BD BIOSCIENCES
Oncology, the study of cancer, is a complex area of human disease with many challenges including heterogeneity of disease and limited samples. Throughout the world, BD Biosciences tools help clinical researchers study genes, proteins, and cells to better understand disease, improve diagnosis and disease management, and facilitate the discovery and development of novel therapeuti
BLOOD CELL DISORDER RESEARCH
BD Biosciences supports leukemia clinical research with a broad range of immunophenotyping reagents and tools for flow cytometric applications, supporting among others scientists who are studying the biological aspects of Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).
The process of diagnosis, classification, treatment, and monitoring of leukemia and lymphoma patients is complex and continuously evolving.
Over the past years BD Biosciences has been working with several independent European Working Groups – i.e., ERIC, NOPHO, I-BFM – and independent Consortia in Europe, as well as in US, in the standardization of their processes. Standardization of processes improves the quality of results, and ultimately the diagnosis and treatment of leukemia patients.
In addition, BD Biosciences started to collaborate with the EuroFlow™ Consortium, a scientifically independent network, supported by the European Commission (grant LSHB-CT-2006-018708) for the specific targeted research project “Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies”.